Vitasora Health Limited

As of June 30, 2025, VITASORA HEALTH LTD. carries a market capitalization of 92.91M, placing it among publicly traded companies globally. Its enterprise value stands at 92.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

VITASORA HEALTH LTD.'s next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2025, VITASORA HEALTH LTD. has 1.57B shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 40.39, and the price-to-book ratio stands at 9.62.

These figures are as of June 30, 2025. The EV/Sales ratio of 45.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 92.68M versus a market cap of 92.91M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, VITASORA HEALTH LTD. maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, VITASORA HEALTH LTD. posted a negative return on equity (ROE) of -117.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -74.29, reflecting losses generated across the asset base. Inventory turnover of 0.01 indicates how many times VITASORA HEALTH LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, VITASORA HEALTH LTD. recorded 813.48 in income tax expense. The company reported a pretax loss of -6.65M and -6.65M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on July 17, 2026, VITASORA HEALTH LTD.'s stock has declined approximately 94.79% over the past 52 weeks.

Over the twelve months ended June 30, 2025, VITASORA HEALTH LTD. generated 2.04M in revenue and converted that into -6.65M in net income, yielding earnings per share of 0.00. EBITDA reached -7.01M, while operating income came in at -7.05M.

As of June 30, 2025, VITASORA HEALTH LTD. holds 276,010.93 in cash and equivalents against 37,789.92 in total debt, resulting in a net debt position of -259,470.84. Total book value stands at 9.65M, with working capital of 1.10M providing operational flexibility.

Over the twelve months ended June 30, 2025, VITASORA HEALTH LTD. posted a gross margin of 99.03, reflecting its pricing power and cost economics. The operating margin of -346.33 and net profit margin of -326.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -5.43, meaning VITASORA HEALTH LTD. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

VITASORA HEALTH LTD.'s most recent stock split took place on May 23, 2016 with a 47:48 split ratio.

As of June 30, 2025, VITASORA HEALTH LTD. has an Altman Z-Score of -22.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.